You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR OXYMETHOLONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OXYMETHOLONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00243399 ↗ Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia Completed FDA Office of Orphan Products Development Phase 1 2004-07-01 The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot).
NCT00243399 ↗ Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia Completed Children's Hospital Medical Center, Cincinnati Phase 1 2004-07-01 The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot).
NCT01001598 ↗ Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita Terminated Boston Children's Hospital Phase 1/Phase 2 2009-11-01 Fanconi anemia (FA) and Dyskeratosis congenita (DC) are inherited bone marrow failure syndromes. The current androgen treatments (e.g., oxymetholone) used to treat FA and DC can cause unwanted masculinizing side effects, indicating a need for a different medication. Danazol is a less potent androgen,and may therefore have fewer masculinizing side effects. Danazol is currently approved by the Food and Drug Administration (FDA) for the treatment of other diseases, but it has never been studied in patients with FA and DC. The main purpose of this study is to see if danazol is a safe treatment for FA and DC. Specifically,we would like to determine: - the best dose of danazol; - how fast hemoglobin (a protein that carries oxygen in the blood) levels rise in FA and DC patients receiving danazol therapy; and - the genetic pattern (known as expression profile) of certain cells in response to danazol, which can predict how well people respond to the medication. Subjects who enroll in the study will be treated with danazol for up to 24 weeks (about 6 months), and will have up to 11 study visits, including followup visits at 38 weeks (9 months) and 52 weeks (one year).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OXYMETHOLONE

Condition Name

Condition Name for OXYMETHOLONE
Intervention Trials
Fanconi Anemia 2
Dyskeratosis Congenita 1
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OXYMETHOLONE
Intervention Trials
Fanconi Anemia 2
Anemia 2
Fanconi Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OXYMETHOLONE

Trials by Country

Trials by Country for OXYMETHOLONE
Location Trials
United States 2
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OXYMETHOLONE
Location Trials
Massachusetts 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OXYMETHOLONE

Clinical Trial Phase

Clinical Trial Phase for OXYMETHOLONE
Clinical Trial Phase Trials
Phase 4 1
Phase 1/Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OXYMETHOLONE
Clinical Trial Phase Trials
Completed 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OXYMETHOLONE

Sponsor Name

Sponsor Name for OXYMETHOLONE
Sponsor Trials
FDA Office of Orphan Products Development 1
Children's Hospital Medical Center, Cincinnati 1
Boston Children's Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OXYMETHOLONE
Sponsor Trials
Other 5
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.